Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057915 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00057915 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 4 participants.
The verdict
NCT00057915, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's white blood cells mixed with peptides may make the body build an immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with refractory stage IV cancer.
Interventions
- BIOLOGICAL CEA peptide 1-6D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2003-09 |
| Est. Completion | 2006-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057915
The ClinicalTrials.gov registry entry for NCT00057915 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CEA peptide 1-6D is the first listed.
NCT00057915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057915 about?
NCT00057915 is a clinical study titled "Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer". RATIONALE: Vaccines made from a person's white blood cells mixed with peptides may make the body build an immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with refractory stage IV cancer.
What is the current status of trial NCT00057915?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2003-09. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00057915?
The interventions under investigation include: CEA peptide 1-6D (BIOLOGICAL).
Who is sponsoring clinical trial NCT00057915?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.